Home › Recently closed › 2026-07248
Financial Transparency and Efficiency of the Prescription Drug User Fee Act, Biosimilar User Fee Act, and Generic Drug User Fee Amendments; Public Meeting; Request for Comments
Comment period closed: closed 86 days ago (Jul 23, 2026).
Read on FederalRegister.gov · Official PDF · Docket on Regulations.gov · Add to calendar (.ics)
Summary (from the Federal Register abstract)
The Food and Drug Administration (FDA or the Agency) is announcing the following public meeting titled "Financial Transparency and Efficiency of the Prescription Drug User Fee Act, Biosimilar User Fee Act, and Generic Drug User Fee Amendments." The topic to be discussed is the financial transparency and efficiency of the Prescription Drug User Fee Act, Biosimilar User Fee Act, and Generic Drug User Fee Amendments.
- Document type
- Notice
- Federal Register document number
- 2026-07248
- Published
- Apr 15, 2026
- Action
- Notice of public meeting; request for comments.
- Docket
- FDA-2026-N-3273
- Comments posted on Regulations.gov (at last check)
- 0
- DATES section (from the document)
- The public meeting will be held on June 23, 2026, from 1:00 p.m. to 2:30 p.m. ET. Either electronic or written comments on this public meeting must be submitted by July 23, 2026. See the SUPPLEMENTARY INFORMATION section for registration date and information.
- Topics (auto-tagged)
- Vaccines / biologics
Source: Federal Register API, document 2026-07248. Federal Register text is a U.S. government work. Confirm dates in the official document; later documents may extend, reopen or correct them.